May 2016

• A 70-year old male with metastatic HCC involving the lung and bone confirmed by biopsy, experiencing mild bone pain
• ECOG=1
• Child-Pugh A
• Therapy was initiated with sorafenib at 400 BID
• Patient experienced grade 1 HTN and grade 1 hand-foot skin reaction, which was managed effectively

April 2017

• Documented radiographic progression
• Therapy with regorafenib at 160mg was initiated
• Patient experienced grade 1 HTN, grade 2 hand-foot skin reaction